Abstract:Decreasing glycemic variability (GV) is become a criterion of glycemic control and important goal in the treatment of diabetes. Despite this importance there are only a few reports on GV using continuous glucose monitoring (CGM) patients with T2D on basal insulin. The aim of this exploratory study was to compare the GV after 12 weeks of treatment on Glargine-100U (Glar-100) or Glargine-300U (Glar-300) in T2D patients. Methods: This is 12-week, randomized with parallel arms. Ninety-four T2D subjects >18 y old with HbA1c between 7.5% -11% (9.2±0.9%) on NPH insulin ÷ OAD, were randomized to Glar-100 or Glar-300. A blinded CGM was inserted in a baseline (run-in) and after 12-week patient- driven titration period. The CGM parameter included TIR (70-180mg/dl), MAGE, CV, time in hypoglycemia and in hyperglycemia ranges were uploaded by carelink software and the GV parameters were analyzed by Glyculator software. Results: No differences between groups was found in any analysed GV parameter. The final HbA1c were similar to Glar-100 and Glar-300(8.0±1.12 and 8.15±1.04), however there were a significant difference regarding on total hypoglycemic events verified by self-monitoring blood glucose (SMBG) Glar-100 and Glar-300 groups (0.44±0.43 vs. 0.25± 0.42 episodes/patient/year respectively, p= 0.007). In exploratory analysis in the quartile that reached the HbA1c <7.4% TIR for Glar-300 group was 75.43% and 65.62% for Glar-100 (NS). Conclusion: In this exploratory study, even when we could not detect differences between GV parameters (probably due to not reaching target glycemic control), the lower risk of hypoglycemia with Glar-300 compared to Glar-100 can still be clearly shown. A tendency for longer TIR stay in the Glar-300 group vs. in the Glar-100 group was seen in the subgroup of those who reached close-to-target A1c values. Disclosure D.R. Franco: Advisory Panel; Self; Abbott, Medtronic, Novo Nordisk A/S, Sanofi. Research Support; Self; Sanofi. Speaker’s Bureau; Self; Abbott, AstraZeneca, Medtronic. G.D. Visconti: None. C. Feder: None. J. Baptista: None. A.G. Vianna: Board Member; Self; Abbott, Medtronic, Novo Nordisk A/S. Research Support; Self; Sanofi. Speaker’s Bureau; Self; Lilly Diabetes. M.T. Guimarães: None. F.V. Souza: None. L.A. Tagata: None. F. Eliaschewitz: Advisory Panel; Self; AstraZeneca, Novo Nordisk A/S, Sanofi-Aventis. Research Support; Self; Bayer AG, GlaxoSmithKline plc., Novo Nordisk A/S, Sanofi-Aventis. Speaker’s Bureau; Self; Eli Lilly and Company. Funding Sanofi

Glycemic Variation in Uncontrolled Graves’ Disease Patients with Normal Glucose Metabolism: Assessment by Continuous Glucose Monitoring

Relationship Between Early–phase Insulin Secretion and Blood Glucose Variability in Subject with Normal Glucose Regulation

Establishment Of Normal Reference Ranges For Glycemic Variability In Chinese Subjects Using Continuous Glucose Monitoring

[Characteristics of Real-Life Glucose Profiles Monitored by Continuous Glucose Monitoring System in Persons with Normal Glucose Tolerance].

Relationship of Glucose Variability With Glycated Hemoglobin and Daily Mean Glucose: A Post Hoc Analysis of Data From 5 Phase 3 Studies

Impact of short-term glycemic variability on risk of all-cause mortality in type 2 diabetes patients with well-controlled glucose profile by continuous glucose monitoring: A prospective cohort study

Comparison of CGM-Derived Measures of Glycemic Variability Between Pancreatogenic Diabetes and Type 2 Diabetes Mellitus

Characteristics and clinical significance of daily blood glucose profiles in patients with gestational diabetes mellitus monitored by continuous glucose monitoring system

Relationship Between Hba1c and Continuous Glucose Monitoring in Chinese Population: A Multicenter Study

A Prospective Study on Continuous Glucose Monitoring in Glycogen Storage Disease Type Ia: Toward Glycemic Targets

[Correlation Between the Amplitude of Glucose Excursion and Plasma 8-Iso Prostaglandin F2alpha Level in Subjects with Different Types of Glucose Regulation].

Correlation Between the Amplitude of Glucose Excursion and the Oxidative/antioxidative System in Subjects with Different Types of Glucose Regulation.

Personalized management of hepatic glycogen storage disorders: The role of continuous glucose monitoring

Glucose Metabolism Before and after Radioiodine Therapy of a Patient with Graves' Disease: Assessment by Continuous Glucose Monitoring.

114-LB: An Exploratory Study to Evaluate the Glycemic Variability by Continuous Glucose Monitoring (CGM) with Insulin Glargine 300 U/mL vs. Glargine 100 U/mL in Patients with Type 2 Diabetes

Continuous glucose monitoring metrics in people with liver glycogen storage disease and idiopathic ketotic hypoglycemia: A single-center, retrospective, observational study

Investigating the Relationship between Morning Glycemic Variability and Patient Characteristics Using Continuous Glucose Monitoring Data in Patients with Type 2 Diabetes

Verification of glycemic profiles using continuous glucose monitoring: cases with steroid use, liver cirrhosis, enteral nutrition, or late dumping syndrome

Relationship between key continuous glucose monitoring-derived metrics and specific cognitive domains in patients with type 2 diabetes mellitus

[Glucose Characteristics in Normal Glucose Tolerance Subjects with Metabolic Syndrome].

Continuous Glucose Monitoring in Type 2 Diabetes with Gastroparesis